Abbott Laboratories

A pharmaceuticals health care company.

Based in DC

🤖

AI Overview

With $1.5M in lobbying spend across 30 quarterly filings, Abbott Laboratories is a significant lobbying presence.

$1.5M
Total Lobbying Spend
30
Quarterly Filings
1
Lobbying Firms Used
1
Individual Lobbyists

Spending by Year

YearLobbying Spend
2018$200K
2019$200K
2020$200K
2021$200K
2022$200K
2023$200K
2024$150K
2025$150K

Lobbying Firms

W STRATEGIES, LLC

What They Lobby For

  • FY 2018 Continuing resolution as it relates to suspension of the medical device tax. H.R.4617: Protect Medical Innovation Act.
  • H.R.1892: Bipartisan Budget Act of 2018. H.R.1625: Consolidated Appropriations Act, 2018.
  • Medicare conditions of participation as it relates to antibiotics. Education about the regulation of continuous glucose monitor technologies.
  • Development of legislation regulated to regulation of LDT's, including a discussion draft of Diagnostic Accuracy and Improvement Act. Education about the importance of non-pharmacological pain treatment options, including medical devices. H.R.195, as it relates to the HEALTHY KIDS Act CHIP reauthorization.
  • H.R.4617: Protect Medical Innovation Act.
  • Education about the importance of proper reimbursement for home monitoring services for anticoagulation management. Education about the regulation of continuous glucose monitor technologies including CMS regulation of CGM.
  • Development of legislation regulated to regulation of LDT's, including a discussion draft of Diagnostic Accuracy and Improvement Act. Reauthorization of PAHPA (Pandemic All Hazards Preparedness Act). H.R.6: Support for Patients and Communities Act as it relates to provisions designed to promote the importance of non-pharmacological pain treatment options, including medical devices.
  • Development of legislation regulated to regulation of LDT's, including a discussion draft of Diagnostic Accuracy and Improvement Act. H.R.6378/S.2852: Reauthorization of PAHPA (Pandemic All-Hazards Preparedness Act). H.R.6: Support for Patients and Communities Act as it relates to provisions designed to promote the importance of non-pharmacological pain treatment options, including medical devices.
  • Education around VA coverage of CGM devices.
  • Education about the implementation of PAMA with respect to physician office labs.

Related Investigations

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.